AbCellera is a Canadian biotechnology company headquartered in Vancouver, built around a proprietary antibody discovery platform that it licenses to pharmaceutical and biotech partners developing new drug candidates. Listed on Nasdaq under the ticker ABCL.O, the company gained widespread recognition during the COVID-19 pandemic as the discoverer of bamlanivimab, an antibody treatment developed in partnership with Eli Lilly and Company, which brought both revenue and visibility to a business that had previously operated largely below mainstream investor radar.
The underlying business model is distinctive: rather than advancing drugs through the full clinical pipeline itself, AbCellera acts as an upstream discovery partner, taking royalties and milestones as its partners progress candidates towards commercialisation. That royalty-driven structure gives the company long-term revenue potential largely decoupled from the operational complexity of running clinical trials, though near-term income can be lumpy and heavily dependent on partner development timelines.
Please note this is marketing communication, not recommendation or advice.
cuentas de clientes
FxPro brinda servicios comerciales en línea a clientes desde 1999 y actualmente brinda servicios a 173 países en todo el mundo.
Premios
FxPro ha recibido un reconocimiento constante en la industria, ganando más de 145 premios internacionales hasta la fecha por la calidad de sus servicios.
Servicio al Cliente
Nuestro dedicado equipo de servicio al cliente multilingüe trabaja las 24 horas del día, los 5 días de la semana para brindarle un nivel excepcional de soporte.
regulaciones de la industria
FxPro opera bajo estricta supervisión regulatoria en múltiples jurisdicciones, incluida la autorización de la FCA en el Reino Unido, uno de los reguladores financieros más confiables a nivel mundial.
